A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
Hariprasad Thangavel(Hackensack Meridian Health), Meghana V. Trivedi(University of Houston), Suhas Vasaikar(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Herbert Levine(Center for Theoretical Biological Physics), Michael T. Lewis(Baylor College of Medicine), Sufeng Mao(Baylor College of Medicine), Lacey E. Dobrolecki(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine), Chandandeep Nagi(Icahn School of Medicine at Mount Sinai), Agostina Nardone(AstraZeneca (Spain)), Mario Giuliano(Regione Campania), Mothaffar F. Rimawi(Baylor College of Medicine), Mohit Kumar Jolly(Center for Theoretical Biological Physics), Noor Mazin Abdulkareem(University of Houston), Bing Zhang(Baylor College of Medicine), Fengju Chen(Baylor College of Medicine), Raksha R. Bhat(University of Houston), Tanya Kumar(University of Houston), Jason T. George(Baylor College of Medicine)
Cited by 43
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k